An uncommon mature T-cell lymphoma of intraepithelial lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum. Other less frequent primary anatomic sites include th...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation on enteropathy-associated T-cell lymphoma is limited due to its rarity and the complexity of its clinical presentation. Because EATL affects a small number of individuals globally, systematic clinical studies have been scarce. Additionally, the relationship between EATL and conditions like celiac disease complicates its characterization, making it challenging to gather comprehensive clinical data.
To navigate your care effectively, seek a hematologist or oncologist with expertise in lymphomas, particularly those familiar with T-cell lymphomas. Additionally, consider reaching out to major cancer centers that may have specialized programs for rare lymphomas. You can find resources and support through the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov. Although no specific patient organizations are identified for EATL, participating in clinical trials may provide access to cutting-edge treatments and contribute to the understanding of this condition.
Currently, there are several orphan drugs designated for the treatment of enteropathy-associated T-cell lymphoma, including Belinostat, cerdulatinib, and mogamulizumab. Additionally, there are 8 active clinical trials investigating various treatment options. For more information on these trials, you can visit ClinicalTrials.gov and search for enteropathy-associated T-cell lymphoma: https://clinicaltrials.gov/search?cond=enteropathy-associated%20T-cell%20lymphoma. This research landscape offers hope for improved treatment strategies in the future.
Actionable guidance for navigating care for enteropathy-associated T-cell lymphoma
To navigate your care effectively, seek a hematologist or oncologist with expertise in lymphomas, particularly those familiar with T-cell lymphomas. Additionally, consider reaching out to major cancer centers that may have specialized programs for rare lymphomas. You can find resources and support through the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov. Although no specific patient organizations are identified for EATL, participating in clinical trials may provide access to cutting-edge treatments and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation on enteropathy-associated T-cell lymphoma is limited due to its rarity and the complexity of its clinical presentation. Because EATL affects a small number of individuals globally, systematic clinical studies have been scarce. Additionally, the relationship between EATL and conditions like celiac disease complicates its characterization, making it challenging to gather comprehensive clinical data.
To navigate your care effectively, seek a hematologist or oncologist with expertise in lymphomas, particularly those familiar with T-cell lymphomas. Additionally, consider reaching out to major cancer centers that may have specialized programs for rare lymphomas. You can find resources and support through the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov. Although no specific patient organizations are identified for EATL, participating in clinical trials may provide access to cutting-edge treatments and contribute to the understanding of this condition.
Currently, there are several orphan drugs designated for the treatment of enteropathy-associated T-cell lymphoma, including Belinostat, cerdulatinib, and mogamulizumab. Additionally, there are 8 active clinical trials investigating various treatment options. For more information on these trials, you can visit ClinicalTrials.gov and search for enteropathy-associated T-cell lymphoma: https://clinicaltrials.gov/search?cond=enteropathy-associated%20T-cell%20lymphoma. This research landscape offers hope for improved treatment strategies in the future.
Actionable guidance for navigating care for enteropathy-associated T-cell lymphoma
To navigate your care effectively, seek a hematologist or oncologist with expertise in lymphomas, particularly those familiar with T-cell lymphomas. Additionally, consider reaching out to major cancer centers that may have specialized programs for rare lymphomas. You can find resources and support through the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov. Although no specific patient organizations are identified for EATL, participating in clinical trials may provide access to cutting-edge treatments and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation on enteropathy-associated T-cell lymphoma is limited due to its rarity and the complexity of its clinical presentation. Because EATL affects a small number of individuals globally, systematic clinical studies have been scarce. Additionally, the relationship between EATL and conditions like celiac disease complicates its characterization, making it challenging to gather comprehensive clinical data.
To navigate your care effectively, seek a hematologist or oncologist with expertise in lymphomas, particularly those familiar with T-cell lymphomas. Additionally, consider reaching out to major cancer centers that may have specialized programs for rare lymphomas. You can find resources and support through the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov. Although no specific patient organizations are identified for EATL, participating in clinical trials may provide access to cutting-edge treatments and contribute to the understanding of this condition.
Currently, there are several orphan drugs designated for the treatment of enteropathy-associated T-cell lymphoma, including Belinostat, cerdulatinib, and mogamulizumab. Additionally, there are 8 active clinical trials investigating various treatment options. For more information on these trials, you can visit ClinicalTrials.gov and search for enteropathy-associated T-cell lymphoma: https://clinicaltrials.gov/search?cond=enteropathy-associated%20T-cell%20lymphoma. This research landscape offers hope for improved treatment strategies in the future.
Actionable guidance for navigating care for enteropathy-associated T-cell lymphoma
To navigate your care effectively, seek a hematologist or oncologist with expertise in lymphomas, particularly those familiar with T-cell lymphomas. Additionally, consider reaching out to major cancer centers that may have specialized programs for rare lymphomas. You can find resources and support through the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov. Although no specific patient organizations are identified for EATL, participating in clinical trials may provide access to cutting-edge treatments and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 9 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.